Arsenic trioxide
| File:Arsenic trioxide.png | |
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 75% bound |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | As2O3 |
| Molar mass | 197.841 g/mol |
|
WikiDoc Resources for Arsenic trioxide |
|
Articles |
|---|
|
Most recent articles on Arsenic trioxide Most cited articles on Arsenic trioxide |
|
Media |
|
Powerpoint slides on Arsenic trioxide |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Arsenic trioxide at Clinical Trials.gov Trial results on Arsenic trioxide Clinical Trials on Arsenic trioxide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Arsenic trioxide NICE Guidance on Arsenic trioxide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Arsenic trioxide Discussion groups on Arsenic trioxide Patient Handouts on Arsenic trioxide Directions to Hospitals Treating Arsenic trioxide Risk calculators and risk factors for Arsenic trioxide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Arsenic trioxide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Arsenic trioxide is the most important commercial compound of arsenic, and the main starting material for arsenic chemistry. It is the highly toxic byproduct of certain kinds of ore processing, for example gold mining.[1]
Preparation
- Burning arsenic in air.
- Hydrolysis of arsenic trichloride.
- Roasting of arsenide minerals. (Main industrial route)
Chemical properties
Arsenic trioxide is an amphoteric oxide which shows a marked preponderance for its acidic properties. It dissolves readily in alkaline solutions to give arsenites. It is much less soluble in acids, but will dissolve in hydrochloric acid to give arsenic trichloride or related species. It reacts with oxidizing agents such as ozone, hydrogen peroxide and nitric acid to give arsenic pentoxide, As2O5: the reaction with hydrogen peroxide can be explosive. It is also readily reduced to arsenic, and arsine (AsH3) may also be formed.
Molecular structure
Tetrahedral molecules, As4O6, in α-form and in liquid and gas phases.
Uses
- Starting point for the manufacture of arsenic-based pesticides .(sodium arsenite, sodium arsenate, sodium cacodylate).
- Starting point for the manufacture of certain arsenic-based pharamaceuticals (Neosalvarsan) and veterinary products.
- Decolorizing agent for glasses and enamels.
- Preservative for wood.
- Hydrogen recombination poison for metallurgical studies.
- Starting point for the preparation of elemental arsenic, arsenic alloys and arsenide semiconductors.
- Use as a cytostatic in the treatment of refractory promyelocytic (M3) subtype of acute myeloid leukemia. The drug is available as Trisenox® ampules; each containing 10mg to be diluted for i.v. infusion.
- Arsenic trioxide is also used to treat leukemia in patients who have not responded to other medications.
Medical applications
Arsenic trioxide under the trade name Trisenox (manufacturer: Cephalon) is a chemotheraputic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. Due to the toxic nature of arsenic, this drug carries significant risks.
The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.[2]
Toxicology
- See also: arsenicosis.
Arsenic trioxide is readily absorbed by the digestive system: toxic effects are also well known after inhalation of the dust or fumes and after skin contact. Elimination is rapid at first (half-life of 1–2 days), by methylation to cacodylic acid and excretion in the urine, but a certain amount (30–40% in the case of repeated exposure) is incorporated into the bones, muscles, skin, hair and nails (all tissues rich in keratin) and eliminated over a period of weeks or months.
The first symptoms of acute arsenic poisoning by ingestion are digestive problems: vomiting, abdominal pains, diarrhea often accompanied by bleeding. Sub-lethal doses can lead to convulsions, cardiovascular problems, inflammation of the liver and kidneys and abnormalities in the coagulation of the blood. These are followed by the appearance of characteristic white lines (Mees stripes) on the nails and by hair loss. Lower doses lead to liver and kidney problems and to changes in the pigmentation of the skin.
Cases of acute arsenic poisoning are known after inhalation and after skin contact with arsenic trioxide. The first signs are severe irritation, either of the respiratory tract or of the exposed skin, followed by longer term neurological problems. Even dilute solutions of arsenic trioxide are dangerous on contact with the eyes.
Chronic arsenic poisoning is known as arsenicosis: it is found after professional exposure (for example, in metal smelters), in populations whose drinking water contains high levels of arsenic (0.3–0.4 ppm) and in patients treated for long periods with arsenic-based pharmaceuticals.
Arsenic trioxide has been shown to be a human carcinogen. Studies on workers exposed in copper foundries in the U.S., Japan and Sweden indicate a risk of lung cancer 6–10 times higher for the most exposed workers compared with the general population. Long-term ingestion of arsenic trioxide either in drinking water or as a medical treatment can lead to skin cancer. Reproductive problems (high incidence of miscarriage, low birth weight, congenital deformations) have also been indicated in one study of women exposed to arsenic trioxide dust as employees or neighbours of a copper foundry.
Bibliography
- Institut national de recherche et de sécurité (INRS), Fiche toxicologique nº 89 : Trioxyde de diarsenic, 1989.
- AFHS Database on use as a cytostatic
References
- ↑ "Giant Mine - Northwest Territories Region - Indian and Northern Affairs Canada". Retrieved 2007-08-28.
- ↑ Lu J, Chew EH, Holmgren A (2007). "Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide". Proc. Natl. Acad. Sci. U.S.A. 104 (30): 12288–93. doi:10.1073/pnas.0701549104. PMID 17640917.
External links
- Case Studies in Environmental Medicine: Arsenic Toxicity
- IARC Monograph – Arsenic and Arsenic Compounds
- International Chemical Safety Card 0378
- NIOSH Pocket Guide to Chemical Hazards
- NTP Report on Carcinogens – Inorganic Arsenic Compounds
- Use of Arsenic Trioxide in Multiple Myeloma Treatment
- The use of Arsenic trioxide in medicine.
- Template:Inrs
cs:Oxid arsenitý de:Arsen(III)-oxid eo:Arseniko it:Claudetite hu:Arzenolit nl:Arsenoliet no:Arsenikk nn:Arsenikk sl:Arzenov trioksid sr:Арсенолит fi:Arseenitrioksidi sv:Arseniktrioxid uk:Клодетит
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Arsenic compounds
- Oxides
- IARC Group 1 carcinogens
- Alchemical substances